STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Guardant Health Director Steve E. Krognes received new equity compensation grants on June 18, 2025, consisting of:

  • Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, exercisable until June 18, 2035
  • Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis

Both grants feature a one-year cliff vesting schedule, maturing on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be part of standard director compensation. The filing was submitted by John Saia as attorney-in-fact for Krognes on June 20, 2025.

Steve E. Krognes, Direttore di Guardant Health, ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, che comprendono:

  • Opzioni su azioni: 6.833 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di 50,57 $ per azione, esercitabili fino al 18 giugno 2035
  • Unità di Azioni Vincolate (RSU): 4.203 RSU senza costo iniziale

Entrambe le assegnazioni prevedono un periodo di maturazione con cliff di un anno, che scade il 18 giugno 2025 o alla data della prossima assemblea annuale degli azionisti, a seconda di quale evento si verifichi per primo. Il pacchetto retributivo sembra far parte della normale compensazione per i direttori. La comunicazione è stata presentata da John Saia in qualità di procuratore per Krognes il 20 giugno 2025.

Steve E. Krognes, Director de Guardant Health, recibió nuevas concesiones de compensación en acciones el 18 de junio de 2025, que consisten en:

  • Opciones sobre acciones: 6,833 opciones para comprar acciones ordinarias a un precio de ejercicio de $50.57 por acción, ejercibles hasta el 18 de junio de 2035
  • Unidades de acciones restringidas (RSU): 4,203 RSU sin costo inicial

Ambas concesiones tienen un calendario de adquisición con cliff de un año, que vence el 18 de junio de 2025 o en la fecha de la próxima junta anual de accionistas, lo que ocurra primero. El paquete de compensación parece ser parte de la compensación estándar para directores. La presentación fue realizada por John Saia como apoderado de Krognes el 20 de junio de 2025.

Guardant Health 이사 Steve E. Krognes는 2025년 6월 18일에 다음과 같은 신규 주식 보상 부여를 받았습니다:

  • 스톡 옵션: 주당 $50.57의 행사가격으로 보통주 6,833주를 구매할 수 있는 옵션, 2035년 6월 18일까지 행사 가능
  • 제한 주식 단위(RSU): 무상으로 4,203 RSU 부여

두 보상 모두 1년 cliff 베스팅 스케줄이 적용되며, 2025년 6월 18일 또는 다음 연례 주주총회일 중 먼저 도래하는 날짜에 만료됩니다. 이 보상 패키지는 일반적인 이사 보상의 일부로 보입니다. 이 제출 서류는 2025년 6월 20일 John Saia가 Krognes를 대리하여 제출했습니다.

Steve E. Krognes, administrateur de Guardant Health, a reçu de nouvelles attributions de compensation en actions le 18 juin 2025, comprenant :

  • Options d'achat d'actions : 6 833 options d'achat d'actions ordinaires à un prix d'exercice de 50,57 $ par action, exerçables jusqu'au 18 juin 2035
  • Unités d'actions restreintes (RSU) : 4 203 RSU sans coût initial

Les deux attributions comportent une période d'acquisition avec cliff d'un an, arrivant à échéance soit le 18 juin 2025, soit à la date de la prochaine assemblée annuelle des actionnaires, selon la première éventualité. Le package de rémunération semble faire partie de la compensation standard des administrateurs. Le dépôt a été soumis par John Saia en tant que mandataire de Krognes le 20 juin 2025.

Steve E. Krognes, Direktor von Guardant Health, erhielt am 18. Juni 2025 neue Aktienvergütungszuteilungen, bestehend aus:

  • Aktienoptionen: 6.833 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 50,57 $ pro Aktie, ausübbar bis zum 18. Juni 2035
  • Restricted Stock Units (RSUs): 4.203 RSUs ohne Anschaffungskosten

Beide Zuteilungen unterliegen einem einjährigen Cliff-Vesting-Zeitplan, der entweder am 18. Juni 2025 oder am Datum der nächsten jährlichen Hauptversammlung fällig wird, je nachdem, was zuerst eintritt. Das Vergütungspaket scheint Teil der üblichen Direktorenvergütung zu sein. Die Meldung wurde am 20. Juni 2025 von John Saia als Bevollmächtigter für Krognes eingereicht.

Positive
  • None.
Negative
  • None.

Steve E. Krognes, Direttore di Guardant Health, ha ricevuto nuove assegnazioni di compensi azionari il 18 giugno 2025, che comprendono:

  • Opzioni su azioni: 6.833 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di 50,57 $ per azione, esercitabili fino al 18 giugno 2035
  • Unità di Azioni Vincolate (RSU): 4.203 RSU senza costo iniziale

Entrambe le assegnazioni prevedono un periodo di maturazione con cliff di un anno, che scade il 18 giugno 2025 o alla data della prossima assemblea annuale degli azionisti, a seconda di quale evento si verifichi per primo. Il pacchetto retributivo sembra far parte della normale compensazione per i direttori. La comunicazione è stata presentata da John Saia in qualità di procuratore per Krognes il 20 giugno 2025.

Steve E. Krognes, Director de Guardant Health, recibió nuevas concesiones de compensación en acciones el 18 de junio de 2025, que consisten en:

  • Opciones sobre acciones: 6,833 opciones para comprar acciones ordinarias a un precio de ejercicio de $50.57 por acción, ejercibles hasta el 18 de junio de 2035
  • Unidades de acciones restringidas (RSU): 4,203 RSU sin costo inicial

Ambas concesiones tienen un calendario de adquisición con cliff de un año, que vence el 18 de junio de 2025 o en la fecha de la próxima junta anual de accionistas, lo que ocurra primero. El paquete de compensación parece ser parte de la compensación estándar para directores. La presentación fue realizada por John Saia como apoderado de Krognes el 20 de junio de 2025.

Guardant Health 이사 Steve E. Krognes는 2025년 6월 18일에 다음과 같은 신규 주식 보상 부여를 받았습니다:

  • 스톡 옵션: 주당 $50.57의 행사가격으로 보통주 6,833주를 구매할 수 있는 옵션, 2035년 6월 18일까지 행사 가능
  • 제한 주식 단위(RSU): 무상으로 4,203 RSU 부여

두 보상 모두 1년 cliff 베스팅 스케줄이 적용되며, 2025년 6월 18일 또는 다음 연례 주주총회일 중 먼저 도래하는 날짜에 만료됩니다. 이 보상 패키지는 일반적인 이사 보상의 일부로 보입니다. 이 제출 서류는 2025년 6월 20일 John Saia가 Krognes를 대리하여 제출했습니다.

Steve E. Krognes, administrateur de Guardant Health, a reçu de nouvelles attributions de compensation en actions le 18 juin 2025, comprenant :

  • Options d'achat d'actions : 6 833 options d'achat d'actions ordinaires à un prix d'exercice de 50,57 $ par action, exerçables jusqu'au 18 juin 2035
  • Unités d'actions restreintes (RSU) : 4 203 RSU sans coût initial

Les deux attributions comportent une période d'acquisition avec cliff d'un an, arrivant à échéance soit le 18 juin 2025, soit à la date de la prochaine assemblée annuelle des actionnaires, selon la première éventualité. Le package de rémunération semble faire partie de la compensation standard des administrateurs. Le dépôt a été soumis par John Saia en tant que mandataire de Krognes le 20 juin 2025.

Steve E. Krognes, Direktor von Guardant Health, erhielt am 18. Juni 2025 neue Aktienvergütungszuteilungen, bestehend aus:

  • Aktienoptionen: 6.833 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 50,57 $ pro Aktie, ausübbar bis zum 18. Juni 2035
  • Restricted Stock Units (RSUs): 4.203 RSUs ohne Anschaffungskosten

Beide Zuteilungen unterliegen einem einjährigen Cliff-Vesting-Zeitplan, der entweder am 18. Juni 2025 oder am Datum der nächsten jährlichen Hauptversammlung fällig wird, je nachdem, was zuerst eintritt. Das Vergütungspaket scheint Teil der üblichen Direktorenvergütung zu sein. Die Meldung wurde am 20. Juni 2025 von John Saia als Bevollmächtigter für Krognes eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Krognes Steve E.

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $50.57 06/18/2025 A 6,833 (1) 06/18/2035 Common Stock 6,833 $0 6,833 D
Restricted Stock Units $0 06/18/2025 A 4,203 (2) (3) Common Stock 4,203 $0 4,203 D
Explanation of Responses:
1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John Saia, as attorney-in-fact for Steve Krognes 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did GH director Steve Krognes receive on June 18, 2025?

Steve Krognes received 6,833 stock options with an exercise price of $50.57 per share. These options will fully vest on June 18, 2026 (one-year anniversary) or the date of the next annual stockholders meeting, whichever comes earlier. The options expire on June 18, 2035.

How many Restricted Stock Units (RSUs) were granted to Steve Krognes at Guardant Health (GH)?

Steve Krognes was granted 4,203 Restricted Stock Units (RSUs) on June 18, 2025. These RSUs will vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever occurs earlier.

What is Steve Krognes's role at Guardant Health (GH)?

According to the Form 4 filing, Steve Krognes serves as a Director on Guardant Health's Board of Directors. This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

When will Steve Krognes's GH stock options and RSUs vest?

Both the stock options and RSUs granted to Steve Krognes will vest in full on the earlier of: (1) June 18, 2026 (the one-year anniversary of the grant date) or (2) the date of the next annual stockholders meeting.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

6.01B
118.13M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO